These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 9375287)

  • 1. Skin involvement as a relevant outcome measure in clinical trials of systemic sclerosis.
    Seibold JR; McCloskey DA
    Curr Opin Rheumatol; 1997 Nov; 9(6):571-5. PubMed ID: 9375287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Systemic sclerosis (scleroderma) without scleroderma].
    Nadashkevych ON
    Lik Sprava; 2001; (3):93-4. PubMed ID: 11560041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome measurement in scleroderma clinical trials.
    Pope JE; Bellamy N
    Semin Arthritis Rheum; 1993 Aug; 23(1):22-33. PubMed ID: 8235663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variability of skin scores and clinical measurements in scleroderma.
    Pope JE; Baron M; Bellamy N; Campbell J; Carette S; Chalmers I; Dales P; Hanly J; Kaminska EA; Lee P
    J Rheumatol; 1995 Jul; 22(7):1271-6. PubMed ID: 7562757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study.
    Levy Y; Amital H; Langevitz P; Nacci F; Righi A; Conforti L; Generini S; Matucci Cerinic M; Shoenfeld Y
    Arthritis Rheum; 2004 Mar; 50(3):1005-7. PubMed ID: 15022346
    [No Abstract]   [Full Text] [Related]  

  • 6. Outcome measurements in scleroderma: results from a delphi exercise.
    Gazi H; Pope JE; Clements P; Medsger TA; Martin RW; Merkel PA; Kahaleh B; Wollheim FA; Baron M; Csuka ME; Emery P; Belch JF; Hayat S; Lally EV; Korn JH; Czirjak L; Herrick A; Voskuyl AE; Bruehlmann P; Inanc M; Furst DE; Black C; Ellman MH; Moreland LW; Rothfield NF; Hsu V; Mayes M; McKown KM; Krieg T; Siebold JR
    J Rheumatol; 2007 Mar; 34(3):501-9. PubMed ID: 17299843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nodular scleroderma in systemic sclerosis under D-penicillamine therapy.
    Sasaki T; Denpo K; Ono H; Nakajima H
    J Dermatol; 1992 Dec; 19(12):968-71. PubMed ID: 1293190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phototherapy in systemic sclerosis: Review.
    Chaowattanapanit S; Choonhakarn C; Foocharoen C; Julanon N
    Photodermatol Photoimmunol Photomed; 2017 Nov; 33(6):296-305. PubMed ID: 28703365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scleroderma--clinical and pathological advances.
    Denton CP; Black CM
    Best Pract Res Clin Rheumatol; 2004 Jun; 18(3):271-90. PubMed ID: 15158741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The course of skin involvement in systemic sclerosis over three years in a trial of chlorambucil versus placebo.
    Clements P; Lachenbruch P; Furst D; Paulus H
    Arthritis Rheum; 1993 Nov; 36(11):1575-9. PubMed ID: 8240434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sample size calculations in scleroderma: a rational approach to choosing outcome measurements in scleroderma trials.
    Pope JE; Bellamy N
    Clin Invest Med; 1995 Feb; 18(1):1-10. PubMed ID: 7768060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic sclerosis and localized scleroderma in childhood.
    Zulian F
    Rheum Dis Clin North Am; 2008 Feb; 34(1):239-55; ix. PubMed ID: 18329543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome measures in systemic sclerosis: an update on instruments and current research.
    Khanna D; Merkel PA
    Curr Rheumatol Rep; 2007 May; 9(2):151-7. PubMed ID: 17502046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nodular scleroderma: focally increased tenascin expression differing from that in the surrounding scleroderma skin.
    Mizutani H; Taniguchi H; Sakakura T; Shimizu M
    J Dermatol; 1995 Apr; 22(4):267-71. PubMed ID: 7541812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging targeted therapies in scleroderma lung and skin fibrosis.
    Maurer B; Distler O
    Best Pract Res Clin Rheumatol; 2011 Dec; 25(6):843-58. PubMed ID: 22265265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scleroderma--developing measures of response.
    Furst DE; Khanna D; Mattucci-Cerinic M; Silman AJ; Merkel PA; Foeldvari I;
    J Rheumatol; 2005 Dec; 32(12):2477-80. PubMed ID: 16331791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous and subcutaneous inflammatory sclerosis syndromes.
    Doyle JA; Connolly SM; Winkelmann RK
    Arch Dermatol; 1982 Nov; 118(11):886-90. PubMed ID: 7138043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of vascular damage in scleroderma with angiotensin-converting enzyme (ACE) inhibition.
    Maddison P
    Rheumatology (Oxford); 2002 Sep; 41(9):965-71. PubMed ID: 12209028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic sclerosis sine scleroderma: an unusual presentation in scleroderma renal crisis.
    Molina JF; Anaya JM; Cabrera GE; Hoffman E; Espinoza LR
    J Rheumatol; 1995 Mar; 22(3):557-60. PubMed ID: 7783082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review of systemic sclerosis-specific instruments for the EULAR Outcome Measures Library: An evolutional database model of validated patient-reported outcomes.
    Ingegnoli F; Carmona L; Castrejon I
    Semin Arthritis Rheum; 2017 Apr; 46(5):609-614. PubMed ID: 27839740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.